- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07691515
Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma (RAINBOW)
Transcatheter Arterial Chemoembolization in Combination With Tislelizumab Plus Lenvatinib Versus Systemic Cisplatin Plus Gemcitabine in Combination With Tislelizumab for Unresectable Intrahepatic Cholangiocarcinoma: A Phase III, Multicenter, Randomized Controlled Trial
This is a phase III, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of arterially directed therapy in combination with tislelizumab plus lenvatinib compared with gemcitabine and cisplatin (GEMCIS) in combination with tislelizumab as first-line treatment for patients with unresectable intrahepatic cholangiocarcinoma.
Approximately 140 eligible patients with histologically confirmed unresectable intrahepatic cholangiocarcinoma without extrahepatic metastasis will be enrolled and randomized in a 1:1 ratio to receive either TACE plus tislelizumab and lenvatinib or GEMCIS plus tislelizumab. In the TACE-based treatment arm, hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to the protocol.
The primary endpoint is overall survival. Secondary endpoints include progression-free survival, time to progression, objective response rate, disease control rate, safety, and quality of life.
Aperçu de l'étude
Statut
Les conditions
Type d'étude
Inscription (Estimé)
Phase
- Phase 3
Contacts et emplacements
Coordonnées de l'étude
- Nom: Gaojun Teng, MD
- Numéro de téléphone: +86 13805171500
- E-mail: gjteng@seu.edu.cn
Sauvegarde des contacts de l'étude
- Nom: Binyan Zhong, MD
- Numéro de téléphone: +86 15850522044
- E-mail: byzhongir@sina.com
Lieux d'étude
-
-
Guangdong
-
Guangzhou, Guangdong, Chine, 510060
- The First Affiliated Hospital, Sun Yat-sen University
-
Contact:
- Ming Kuang
- Numéro de téléphone: 020-87755766
- E-mail: kuangm@mail.sysu.edu.cn
-
Contact:
- Zhenwei Peng
- E-mail: pzhenw@mail.sysu.edu.cn
-
Sous-enquêteur:
- Wenzhe Fan
-
Guangzhou, Guangdong, Chine, 510317
- Guangdong Second People's Hospital
-
Contact:
- Chengjiang Xiao
- Numéro de téléphone: +86 13602808387
- E-mail: Xxx196610@163.com
-
Guangzhou, Guangdong, Chine, 510168
- Jinshazhou Hospital of Guangzhou University of Chinese Medicine
-
Contact:
- Liangliang Qiao
- Numéro de téléphone: +86 13544539881
- E-mail: 271937316@qq.com
-
Guangzhou, Guangdong, Chine, 511400
- The Affiliated Panyu Central Hospital of Guangzhou Medical University
-
Contact:
- Fuxi Huang
- Numéro de téléphone: +86 18902299938
- E-mail: Fuxihuang2006@126.com
-
Guangzhou, Guangdong, Chine, 524003
- The Second Affiliated Hospital of Guangdong Medical University
-
Contact:
- Kangshun Zhu
- Numéro de téléphone: +86 13602864242
- E-mail: Zhksh010@163.com
-
Jiangmen, Guangdong, Chine, 529030
- Jiangmen Central Hospital
-
Contact:
- Yuchuang Liang
- Numéro de téléphone: +86 13322888181
- E-mail: jmlyc@21cn.com
-
-
Hubei
-
Wuhan, Hubei, Chine, 430022
- Wuhan Union Hospital of China
-
Contact:
- Xuefeng Kan
- Numéro de téléphone: +86 13545874189
- E-mail: xkliulang1314@163.com
-
-
Hunan
-
Changsha, Hunan, Chine, 410013
- The Third XIANGYA Hospital of Central South University
-
Contact:
- Qi Liang
- Numéro de téléphone: +86 137 8731 8180
- E-mail: csuliangqi10@163.com
-
Changsha, Hunan, Chine, 410011
- The Second Xiangya Hospital of Central South University
-
Contact:
- Yudong Xiao
- Numéro de téléphone: +86 136 3740 3027
- E-mail: xiaoyudong222@csu.edu.cn
-
-
Jiangxi
-
Ganzhou, Jiangxi, Chine, 341000
- Ganzhou Hospital-Nanfang Hospital, Southern Medical University
-
Contact:
- Yusheng Song
- Numéro de téléphone: +86 135 7675 2988
- E-mail: 646993126@qq.com
-
Nanchang, Jiangxi, Chine, 330209
- The First Affiliated Hospital of Nanchang University
-
Contact:
- Junhua Ai
- Numéro de téléphone: +86 18170936163
- E-mail: aijh0001@163.com
-
-
Shandong
-
Qingdao, Shandong, Chine, 266000
- The Affiliated Hospital of Qingdao University
-
Contact:
- Song Wang
- Numéro de téléphone: +86 18661805592
- E-mail: derekqyfy@126.com
-
-
Sichuan
-
Chengdu, Sichuan, Chine, 610041
- West China School of Medicine/West China Hospital, Sichuan University (WCSM/WCH, SCU)
-
Contact:
- Chang Liu
- Numéro de téléphone: +86 18980606382
- E-mail: drliuchang@wchscu.cn
-
-
Zhejiang
-
Hangzhou, Zhejiang, Chine, 310022
- Zhejiang Cancer Hospital
-
Contact:
- Gaojun Teng
- Numéro de téléphone: +86 0571 - 88122222
- E-mail: gjteng@seu.edu.cn
-
Contact:
- Binyan Zhong
- Numéro de téléphone: +86 15850522044
- E-mail: byzhongir@sina.com
-
Sous-enquêteur:
- Jiaping Zheng
-
Jinhua, Zhejiang, Chine, 321000
- Jinhua Municipal Central Hospital
-
Contact:
- Xiaogang Hu
- Numéro de téléphone: +86 135 8866 8173
- E-mail: heartdoctor@163.com
-
Lishui, Zhejiang, Chine, 323020
- Lishui Central Hospital
-
Contact:
- Jiansong Ji
- Numéro de téléphone: +86 0578-2285888
- E-mail: jjstcty@sina.com
-
Contact:
- Jianfei Tu
- E-mail: jianfei1133@163.com
-
Ningbo, Zhejiang, Chine, 315010
- Ningbo No.2 Hospital
-
Contact:
- Yunjie Chen
- Numéro de téléphone: +86 13857877137
- E-mail: a88960317@163.com
-
Ningbo, Zhejiang, Chine, 315048
- Ningbo Medical Center Lihuili Hospital
-
Contact:
- Shengdong Wu
- Numéro de téléphone: +86 13567886669
- E-mail: 13567886669@139.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- Age ≥18 years.
- Histologically confirmed intrahepatic cholangiocarcinoma that is unresectable or recurrent after curative treatment, without extrahepatic metastasis.
- No prior systemic therapy or transarterial interventional therapy for intrahepatic cholangiocarcinoma.
- At least one measurable intrahepatic lesion according to RECIST v1.1.
- ECOG performance status of 0 or 1.
- Child-Pugh class A liver function.
- Life expectancy ≥3 months.
Adequate hematologic, hepatic, renal, and thyroid function within 14 days before study start, defined as:
- Absolute neutrophil count ≥1.5 × 10⁹/L;
- Platelet count ≥75 × 10⁹/L;
- Hemoglobin ≥90 g/L;
- Serum albumin ≥30 g/L;
- Total bilirubin ≤1.5 × upper limit of normal;
- AST and ALT <1.5 × upper limit of normal, and ALP <4 × upper limit of normal;
- TSH <1 × upper limit of normal, with T3 and T4 within the normal range;
- Serum creatinine <1.5 × upper limit of normal and creatinine clearance ≥60 mL/min.
Exclusion Criteria:
- Diffuse infiltrative liver lesions.
- Contraindications to TACE.
- Allergy to intravenous contrast agent.
- pregnant or breastfeeding women, or participants planning pregnancy within 2 years / unwilling to use effective contraception.
- Patients with HIV or syphilis infection.
- Patients with concurrent malignancies or other malignancies within 5 years before enrollment.
- History of allogeneic organ transplantation.
- Severe dysfunction of the heart, kidney, or other organs.
- Severe clinically active infection > grade 2 according to NCI-CTC v5.0.
- Psychiatric illness that may affect the informed consent process; Inability to take oral medications; Participation in another drug clinical trial within 12 months before enrollment.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: TACE Plus Tislelizumab and Lenvatinib
Participants will receive tislelizumab 200 mg intravenously every 3 weeks and oral lenvatinib once daily at a starting dose of 12 mg for body weight ≥60 kg or 8 mg for body weight <60 kg.
TACE will be performed after initiation of lenvatinib and may be repeated based on radiologic response, residual viable tumor, liver function, and investigator assessment.
Both conventional TACE (cTACE) and drug-eluting beads TACE are allowed, and hepatic artery infusion chemotherapy may be added at investigator's discretion.
Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
|
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Oral lenvatinib once daily, 12 mg for participants with body weight ≥60 kg or 8 mg for participants with body weight <60 kg, with dose modification according to toxicity.
Conventional TACE or drug-eluting bead TACE are allowed.
TACE may be repeated based on imaging assessment every 6 weeks ±7 days and investigator judgment.
Optional hepatic arterial infusion chemotherapy with gemcitabine and cisplatin may be administered during or after TACE at the investigator's discretion according to protocol-defined dose ranges.
|
|
Comparateur actif: Gemcitabine-Cisplatin Plus Tislelizumab
Participants will receive cisplatin 25 mg/m² on Day 1 and Day 8, gemcitabine 1000 mg/m² on Days 1 and 8, and tislelizumab 200 mg on Day 1 of each 3-week cycle for up to 8 cycles.
After completion of gemcitabine-cisplatin treatment, participants will continue tislelizumab 200 mg intravenously every 3 weeks.
Treatment will continue until clinical progression, radiologic progressive disease according to RECIST v1.1, completion of 2 years of immunotherapy, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria.
|
Tislelizumab 200 mg intravenously on Day 1 of each 21-day cycle, followed by maintenance tislelizumab every 3 weeks.
Gemcitabine 1000 mg/m² intravenously on Days 1 and 8 of each 21-day cycle, up to 8 cycles.
Cisplatin 25 mg/m² intravenously on Day 1 and Day 8 of each 21-day cycle, up to 8 cycles.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Overall Survival
Délai: From randomization to death from any cause, assessed up to approximately 48 months
|
Overall survival is defined as the time from enrollment/randomization to death from any cause.
Participants who withdraw are lost to follow-up or remain alive at the end of the study will be censored at the date they were last known to be alive.
|
From randomization to death from any cause, assessed up to approximately 48 months
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Progression-Free Survival
Délai: From randomization to disease progression or death, assessed up to approximately 48 months
|
Defined as the time from randomization to disease progression or death from any cause.
Participants without progression or death will be censored at the last date known to be progression-free.
|
From randomization to disease progression or death, assessed up to approximately 48 months
|
|
Time to Progression
Délai: From randomization to disease progression, assessed up to approximately 48 months
|
Defined as the time from randomization to disease progression.
Participants who die without prior progression, withdraw, are lost to follow-up, or remain progression-free at study end will be censored at the last date known to be progression-free.
|
From randomization to disease progression, assessed up to approximately 48 months
|
|
Objective Response Rate
Délai: Assessed every 6 weeks ±7 days, up to approximately 48 months
|
Defined as the proportion of participants achieving complete response or partial response according to RECIST v1.1.
|
Assessed every 6 weeks ±7 days, up to approximately 48 months
|
|
Disease Control Rate
Délai: Assessed every 6 weeks ±7 days, up to approximately 48 months
|
Defined as the proportion of participants achieving complete response, partial response, or stable disease according to RECIST v1.1.
|
Assessed every 6 weeks ±7 days, up to approximately 48 months
|
|
Incidence of Grade ≥3 Adverse Events
Délai: From first dose of study treatment through 28 days after the last dose of study treatment
|
Defined as the occurrence of grade 3 or higher hematologic or non-hematologic toxicities, graded according to CTCAE v5.0.
|
From first dose of study treatment through 28 days after the last dose of study treatment
|
|
Quality of Life Assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)
Délai: Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 is a 30-item questionnaire used to assess health-related quality of life in patients with cancer.
Scores are linearly transformed to a 0 to 100 scale.
For the global health status/quality-of-life scale and functional scales, higher scores indicate better health-related quality of life or functioning.
For symptom scales and single symptom items, higher scores indicate a higher symptom burden or worse symptoms.
|
Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
|
Quality of Life Assessed by the EuroQol Five-Dimension (EQ-5D)
Délai: Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
The EuroQol Five-Dimension Three-Level Questionnaire is a standardized instrument for measuring health-related quality of life.
The descriptive system includes five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.
Each dimension is scored from 1 to 3, where 1 indicates no problems, 2 indicates some or moderate problems, and 3 indicates extreme problems or inability to perform the activity.
Higher scores in each dimension indicate more severe problems or worse health status.
|
Baseline and during treatment/follow-up, assessed up to approximately 48 months
|
Collaborateurs et enquêteurs
Parrainer
Les enquêteurs
- Chercheur principal: Gaojun Teng, MD, Zhejiang Cancer Hospital
- Chercheur principal: Min Kuang, MD, First Affiliated Hospital, Sun Yat-Sen University
- Chercheur principal: Jiansong Ji, MD, The Central Hospital of Lishui City
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs
- Tumeurs par type histologique
- Tumeurs, glandulaires et épithéliales
- Adénocarcinome
- Carcinome
- Cholangiocarcinome
- Cirrhose, familiale, avec hypertension pulmonaire
- Composés hétérocycliques, 1 anneau
- Composés hétérocycliques
- Produits chimiques inorganiques
- Composés de chlore
- Composés d'azote
- Désoxycytidine
- Cytidine
- Nucléosides pyrimidine
- Pyrimidines
- Composés en platine
- Gemcitabine
- Cisplatine
- lenvatinib
- tislelizumab
Autres numéros d'identification d'étude
- RAINBOW 01
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .